In spite of scientific advancement there are some materials that are known for their unique properties and - N-Ethylnorpentedron NEP crystals are one of them These crystals are highly valued for their ...

This announcement is based on a press release statement from Silo Pharma. With a current ratio of 7.9, the company maintains strong liquidity to fund its development pipeline, though analysts tracked ...

Phase 2 randomized study of ELI-002 fully enrolled, with formal interim analysis of disease-free survival (“DFS”) expected in H1 2025; positive results could support rapid advancement into Phase 3 ...

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on ArriVent BioPharma, Inc. (AVBP – Research Report) today and set a price target ...

Ho Junlin, General Counsel of Scholar Rock Holding Corp (NASDAQ:SRRK), recently sold 9,039 shares of the company's common stock. The shares were sold at an average price of $44.1972 each, resulting in ...

SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ('Ainos' or the 'Company'), a pioneer of digiting scent and low-dose interferon therapeutics, today ...

After receiving a complete response letter last week, the other shoe has dropped for Atara Biotherapeutics and its pipeline ...

Humacyte (HUMA) announced that it plans to file an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, ...

This technology holds the potential to revolutionize organ transplantation by enabling the creation of organs suitable for ...

Dyne Therapeutics received fast-track designation from the Food and Drug Administration for a treatment of myotonic dystrophy type 1, a neuromuscular disease.

TVA has selected the BWRX-300 SMR for potential deployment at the Clinch River Site near Oak Ridge, Tennessee.